Erik Greb Treatment with dimethyl fumarate, compared with teriflunomide, is associated with better clinical outcomes in patients with relapsing-remitting multiple sclerosis (MS), according to new research. Time to disability worsening was longer for patients who received dimethyl fumarate, compared with those who received teriflunomide (hazard ratio [HR], 0.58). “Our analysis of real-world data showed that...